导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.71% | 4010/4773 |
| 近一周 | -4.47% | 5222/5467 |
| 近一月 | -4.60% | 1830/5421 |
| 近一季 | -3.48% | 1446/5238 |
| 近半年 | -6.46% | 3348/4931 |
| 近一年 | -17.29% | 3832/4400 |
| 近两年 | 28.72% | 2306/2954 |
| 近三年 | 9.76% | 1750/2253 |
| 成立以来 | 11.59% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.09% 4693/4961 |
9.37% 2487/5312 |
- - |
- - |
| 2025 | 4.49% 3045/4813 |
-6.86% 3405/3635 |
4.56% 737/4076 |
11.52% 3154/4524 |
-3.79% 3340/4813 |
| 2024 | 28.07% 170/3463 |
-4.83% 1774/2808 |
-8.36% 2222/3014 |
43.13% 20/3129 |
2.59% 925/3463 |
| 2023 | 5.53% 186/2656 |
4.22% 1018/2280 |
-2.76% 658/2385 |
8.53% 15/2515 |
-4.04% 851/2655 |
| 2022 | -25.79% 1344/2207 |
-18.50% 1347/1919 |
2.04% 1375/2016 |
-15.97% 1381/2113 |
6.19% 383/2208 |
| 2021 | -3.07% 885/1822 |
-15.10% 1187/1255 |
7.61% 677/1330 |
4.40% 355/1466 |
1.62% 858/1822 |
| 2020 | 21.18% 694/1250 |
-10.68% 800/1028 |
9.55% 789/1067 |
20.01% 63/1164 |
3.19% 937/1184 |
| 2019 | 45.22% 156/1092 |
47.66% 11/754 |
-6.83% 528/804 |
-4.47% 772/850 |
10.49% 128/918 |
| 2018 | -24.89% 336/834 |
- - |
- - |
- - |
-1.05% 8/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证全指证券公司ETF VS. 长安沪深300非周期A(740101) |